Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217990 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT07217990 is a Phase 1 study that has not yet begun recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 84 participants.
The verdict
NCT07217990, a Phase 1 study, has not yet begun recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.
Interventions
- PROCEDURE Biopsy
- RADIATION Radiation Therapy
- PROCEDURE MRI
- DRUG Neoadjuvant Chemotherapy
- PROCEDURE Breast Cancer Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-09-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07217990
The ClinicalTrials.gov registry entry for NCT07217990 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biopsy is the first listed.
NCT07217990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07217990 about?
NCT07217990 is a clinical study titled "Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer". This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.
What is the current status of trial NCT07217990?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-09-15. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07217990?
The interventions under investigation include: Biopsy (PROCEDURE), Radiation Therapy (RADIATION), MRI (PROCEDURE), Neoadjuvant Chemotherapy (DRUG), Breast Cancer Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT07217990?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.